GKOS241018C130000
- 4.20
- +0.20+5.00%
Glaukos Newsroom
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $139
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $139
Buy Rating on Glaukos: IDose's Market Potential and Strategic Advantages Outshine Ripple's RTC-620
Glaukos's Market Position and Mid-Term Growth Prospects Amidst Increased Competition: A Hold Rating Analysis
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $145
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $139
Glaukos Is Maintained at Buy by BTIG
Glaukos Analyst Ratings
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $139
Morgan Stanley Maintains Glaukos(GKOS.US) With Hold Rating, Raises Target Price to $120
A Quick Look at Today's Ratings for Glaukos(GKOS.US), With a Forecast Between $120 to $145
Glaukos Price Target Raised to $140.00/Share From $110.00 by Piper Sandler
Piper Sandler Maintains Overweight on Glaukos, Raises Price Target to $140
Needham Adjusts Glaukos' Price Target to $137 From $131, Keeps Buy Rating
A Quick Look at Today's Ratings for Glaukos(GKOS.US), With a Forecast Between $130 to $145
Glaukos (GKOS) Receives a Buy From Wells Fargo
Analysts' Opinions Are Mixed on These Healthcare Stocks: Glaukos (GKOS) and American Well (AMWL)
Glaukos Analyst Ratings
Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Glaukos (GKOS)
Truist Raises Price Target on Glaukos to $141 From $125, Maintains Buy Rating